Stock On Watch: Why Astrazeneca Plc Reported Big Albireo Pharma, Inc Position?

Stock On Watch: Why Astrazeneca Plc Reported Big Albireo Pharma, Inc Position?

The New Astrazeneca Plc Holding in Albireo Pharma, Inc

Astrazeneca Plc filed with the SEC SC 13D form for Albireo Pharma, Inc. The form can be accessed here: 000119312516767871. As reported in Astrazeneca Plc’s form, the filler as of late owns 16% or 1,008,141 shares of the Health Care–company.

Albireo Pharma, Inc stake is a new one for the and it was filed because of activity on November 3, 2016. We feel this shows Astrazeneca Plc’s positive view for the stock.

Reasons Why Astrazeneca Plc Bought – Albireo Pharma, Inc Stock

Purpose of Transaction

The shares of Common Stock held by AstraZeneca AB were acquiredas a result of the Transaction, when AstraZeneca’s ordinary shares of Albireo were exchanged for shares of Common Stock. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending on variousfactors, including, without limitation, the Issuer’s financial position, the price of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may, in the future, take suchactions with respect to their shares of the Issuer’s capital stock as they deem appropriate, including, without limitation: purchasing additional shares of Common Stock; selling shares of Common Stock; taking any action to change thecomposition of the Issuer’s board of directors; taking any other action with respect to the Issuer or any of its securities in any manner permitted by law or changing their intention with respect to any and all matters referred to in paragraphs(a)through (j)below in this Item4.

CUSIP No.01345P106Schedule 13D Page 5 of 8 Pages

Except as otherwise described in this Schedule, none of the Reporting Persons currently has any plans or proposals that relate to or wouldresult in: (a)the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b)an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving theIssuer or any of its subsidiaries; (c)a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d)any change in the present board of directors or management of the Issuer, including any plans orproposals to change the number or term of directors or to fill any existing vacancies on the board; (e)any material change in the present capitalization or dividend policy of the Issuer; (f)any other material change in the Issuer’sbusiness or corporate structure; (g)any changes in the Issuer’s charter or bylaws or other actions which may impede the acquisition of control of the Issuer by any person; (h)causing a class of securities of the Issuer to bedelisted from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association; (i)causing a class of equity securities of the Issuer to become eligiblefor termination of registration pursuant to Section12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j)any action similar to any of those enumerated above.

Albireo Pharma, Inc Institutional Sentiment

Latest Security and Exchange filings show 34 investors own Albireo Pharma, Inc. The institutional ownership in Q3 2015 is low, at 60.66% of the outstanding shares. This is increased by 1418309 the total institutional shares. 38916338 were the shares owned by these institutional investors. In total 2 funds opened new Albireo Pharma, Inc stakes, 5 increased stakes. There were 10 that closed positions and 16 reduced them.

Rock Springs Capital Management Lp is an institutional investor bullish on Albireo Pharma, Inc, owning 4000000 shares as of Q3 2015 for 0.14% of its portfolio. Kevin Kotler Broadfin Capital Llc owns 5155530 shares or 0.13% of its portfolio. CA Longwood Capital Partners Llc have 0.65% of their stock portfolio for 2548830 shares. Further, Awm Investment Company Inc reported stake worth 0.38% of its US stock portfolio. The CT Great Point Partners Llc owns 3316966 shares. Albireo Pharma, Inc is 0.58% of the manager’s US portfolio.

Business Profile

Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Its clinical pipeline includes over two Phase II product candidates and one Phase III product candidate. Its pipeline includes A4250, A3384 and Elobixibat. The Company is developing A4250 as a treatment for pediatric orphan cholestatic liver diseases, such as progressive familial intrahepatic cholestasis (PFIC). The Company is developing A3384 for the treatment of bile acid malabsorption (BAM) disease. The Company is also developing Elobixibat as a treatment for chronic idiopathic constipation (CIC). A4250 and Elobixibat are selective inhibitors of the ileal bile acid transporter (IBAT). The Company has completed a Phase II clinical trial of a prototype of A3384 in over 19 subjects with BAM.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 0.64 in Q2 2016. Its up 0.14, from 0.5 in 2016Q1. The ratio is positive, as 6 funds sold all Albireo Pharma Inc shares owned while 5 reduced positions. 1 funds bought stakes while 6 increased positions. They now own 5.68 million shares or 19.38% less from 7.05 million shares in 2016Q1.

Renaissance Technologies Limited Com owns 3.57M shares or 0% of their US portfolio. Kcg Hldgs holds 68,782 shares or 0% of its portfolio. Northern Tru Corporation, a Illinois-based fund reported 45,764 shares. Plante Moran Fincl Advsr Ltd owns 1,470 shares or 0% of their US portfolio. Blackrock Fund Advsrs holds 11,195 shares or 0% of its portfolio. Psagot Investment House Limited reported 71,000 shares or 0% of all its holdings. Finemark Bankshares has 0% invested in the company for 7,302 shares. Vanguard Group Incorporated accumulated 0% or 1.53 million shares. Susquehanna Intll Ltd Liability Partnership accumulated 0% or 11,166 shares. Blackrock Institutional Trust Na holds 0% or 25,914 shares in its portfolio. Ameriprise Finance Inc last reported 0% of its portfolio in the stock. Goldman Sachs Incorporated has 17,021 shares for 0% of their US portfolio. Citadel Advsr Limited Com, a Illinois-based fund reported 74,155 shares. Ladenburg Thalmann Serv accumulated 1,000 shares or 0% of the stock. The Illinois-based Group One Trading Lp has invested 0% in Albireo Pharma Inc (NASDAQ:BIOD).

Analysts await Albireo Pharma Inc (NASDAQ:BIOD) to report earnings on December, 15.

The stock closed at $19.46 during the last session. It is down 80.56% since April 4, 2016 and is uptrending. It has outperformed by 75.57% the S&P500.

Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The company has a market cap of $1.25 billion. The Firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. It currently has negative earnings. The Company’s clinical pipeline includes over two Phase II product candidates and one Phase III product candidate.

Albireo Pharma Inc (NASDAQ:BIOD) Ratings Coverage

Out of 2 analysts covering Biodel (NASDAQ:BIOD), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Biodel has been the topic of 2 analyst reports since December 18, 2015 according to StockzIntelligence Inc. Ladenburg Thalmann downgraded Albireo Pharma Inc (NASDAQ:BIOD) on Friday, December 18 to “Neutral” rating. The stock of Albireo Pharma Inc (NASDAQ:BIOD) has “Market Perform” rating given on Friday, December 18 by William Blair.

More notable recent Albireo Pharma Inc (NASDAQ:BIOD) news were published by: Quotes.Wsj.com which released: “News Albireo Pharma Inc.ALBO” on November 03, 2016, also Streetinsider.com with their article: “Form 3 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Sermon Charles” published on November 07, 2016, Streetinsider.com published: “Form 4 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Zorn Peter A” on November 07, 2016. More interesting news about Albireo Pharma Inc (NASDAQ:BIOD) were released by: Marketwired.com and their article: “Biodel Inc. and Albireo Limited Agree to Combine” published on May 25, 2016 as well as Globenewswire.com‘s news article titled: “Albireo Completes Transaction with Biodel to Create Publicly Traded Company …” with publication date: November 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment